US President Donald Trump has announced to impose tariffs on generic medicines imported into America. For the next two years, these medicines will be able to go to America without any duty, but after that the tariff will be 100% and then 200%. What impact will Trump’s decision have on the Indian pharma industry and why has America taken this step? Understand it in 12 easy questions and answers… Question 1: What has Trump announced regarding the tariff on generic medicines? Answer: The US President told on the social media platform Truth Social that from August 1, 2026, zero tariff will continue for the next two years on all generic medicines coming to America. After two years the tariff will be 100% for the next one year and after that it will be 200%. Question 2: What reason has the Trump administration given for imposing such a heavy tariff? Answer: According to Trump, the main objective of this policy is to bring back the manufacturing plants of generic drugs within America. He said that if companies who have been given the deadline do not locate their plants and equipment within the US, they will have to pay tariffs in the form of penalties. However, the existing policy on patented, branded or innovative medicines will remain the same. Question 3: How much generic drugs are used in the US healthcare system? Answer: According to the data of America’s Food and Drug Administration (FDA), generic medicines account for more than 90% of the total medicines prescribed by doctors in America. The healthcare system there is largely dependent on cheap generic medicines. Question 4: What and how much impact will this decision have on India? Answer: India is called the ‘Pharmacy of the World’. If the tariff is increased to 100% and 200%, the cost of Indian medicines will increase significantly in the US market. According to the report of Global Trade Research Initiative (GTRI): In the year 2025, India exported medicines worth a total of $ 25.8 billion i.e. about ₹ 2.49 lakh crore. Out of this, medicines worth 9.7 billion dollars i.e. about ₹ 0.94 lakh crore were exported to America alone. These constitute 38% of the total medicines. According to healthcare analytics firm IQVIA, 47% of the total generic drug prescriptions sold in US pharmacies are filled by Indian companies. Question 5: Will Indian medicines survive in America even after 100% or 200% tariff? Answer: Yes, Indian generic drugs can still remain competitive. According to GTRI report, many Indian generic medicines are sold 7 to 10 times cheaper than branded medicines in the US. In such a situation, even if 100% tariff is imposed, Indian medicines will still remain cheaper than the branded medicines there. Most of this additional cost will ultimately fall on American healthcare providers, insurance companies, and patients, rather than resulting in a complete end to Indian exports. Question 6: Do major Indian pharmaceutical companies already have plants in America? Answer: Yes, some major Indian companies like Sun Pharma, Zydus Lifesciences, Lupin, Aurobindo Pharma, Cipla and Dr. Reddy’s Laboratories operate their plants in America. Cipla is increasing the capacity of its manufacturing plants in Massachusetts and New York. Dr. Reddy’s has said that they are ready to increase production in America if it becomes commercially beneficial. Sun Pharma says that their existing infrastructure in the US is adequate. Question 7: Is it easy to shift production of generic drugs to America? Answer: No, it is a very difficult and expensive deal. The generic medicines business is dependent on the global supply chain. Companies are particularly dependent on India and China for Active Pharmaceutical Ingredients (APIs). Huge capital will be required to set up a new manufacturing ecosystem in America, due to which the prices of medicines in America will increase significantly. Question 8: What steps should India take to deal with this entire situation? Answer: GTRI founder Ajay Srivastava suggests that India needs to work on two fronts: Question 9: How much does Indian medicine save American healthcare? Answer: American people largely take Indian generic medicines for the treatment of diseases like diabetes, high blood pressure, cholesterol, cancer, infectious diseases and mental health. According to the report, Indian medicines alone saved the US healthcare system $219 billion i.e. about ₹21.14 lakh crore in 2022. This savings has been $1.3 trillion over the last decade. Question 10: Which medicines of Indian pharma companies are sold the most in America? Answer: Major Indian companies like Dr. Reddy’s Laboratories, Cipla and Sun Pharma supply to the American market. The top-selling Indian generic drugs in the US include: Question 11: Is this decision part of Trump’s broader tariff strategy? Answer: Yes, the main focus of the Trump administration is to promote American manufacturing and reduce dependence on foreign imports. Even before this, branded drug manufacturers were given tariff exemptions in exchange for manufacturing in the US or reducing prices. Apart from this, America is considering imposing a new tariff of 10% to 12.5% on about 60 countries, under the scope of which India can also come. Question 12: What effect will this have on the bilateral trade agreements between India and America? Answer: America and India have been continuously saying that they are very close to finalizing a bilateral trade agreement. At such a time, this new announcement of imposing heavy tariffs on generic medicines has created new uncertainty in the trade relations between the two countries. Knowledge Part: What are generic medicines? When a company researches and manufactures a new medicine, it gets a patent for a few years. This is called branded medicine. After the patent expires, other companies make cheaper medicines from the same salt/formula, which are called ‘generic medicines’. Their quality and effect are same as branded medicines, but the price is much lower. Tips for Readers and Investors For Pharma Investors: There will be no direct financial impact on Indian companies for the next 2 years as 0% tariff will remain in force. However, in the long term, companies may have to work on a strategy to setup manufacturing facilities in America. Stock Market Watch: Keep an eye on next quarter commentary from companies with US exposure like Cipla, Dr Reddy’s and Sun Pharma.
Source link
[ad_3]
Trump’s new tariff plan on generic drugs in America: 2 years 0%, then 100% and 200% duty; Possible impact on Indian pharmaceutical companies
